GENFIT
Develops therapies and diagnostics for patients with rare and severe liver diseases.
GNFT | PA
Overview
Corporate Details
- ISIN(s):
- FR0004163111 (+2 more)
- LEI:
- 969500XPWN2DMZQA5X73
- Country:
- France
- Address:
- 885 AVENUE EUGENE AVINEE, 59120 LOOS
- Website:
- https://www.genfit.com
Description
GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2014-03-03 17:45 |
Collaboration GENFIT-Sanofi : nouvelle étape clé franchie avec succès
|
French | 731.9 KB | ||
| 2014-03-03 17:45 |
GENFIT –Sanofi Collaboration: Key milestone achieved with success
|
English | 510.6 KB | ||
| 2014-02-26 17:45 |
GENFIT annonce la tenue d’une Assemblée Générale Mixte le 2 avril 2014
|
French | 497.2 KB | ||
| 2014-02-26 17:45 |
GENFIT to hold a Combined General Shareholders’ Meeting on April 2, 2014
|
English | 388.2 KB | ||
| 2014-02-17 17:45 |
La FDA accorde la désignation ‘Fast Track’ pour le GFT505 dans la NASH
|
French | 729.3 KB | ||
| 2014-02-17 17:45 |
The FDA grants Fast Track designation to GFT505 in NASH
|
English | 503.4 KB | ||
| 2014-01-29 08:30 |
GENFIT : Données pré-cliniques soutenant un mécanisme anti-cancéreux de GFT505.
|
French | 751.2 KB | ||
| 2014-01-29 08:30 |
GENFIT : Preclinical data support anti-cancer effects of GFT505
|
English | 539.7 KB | ||
| 2014-01-07 17:45 |
Lancement d’une augmentation de capital d’un montant maximum de 5M€ avec mainti…
|
French | 991.5 KB | ||
| 2014-01-06 17:45 |
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE GENFIT AVEC LA SOCIETE CM-CIC SECURITI…
|
French | 504.4 KB | ||
| 2014-01-06 17:45 |
HALF-YEAR REPORT ON GENFIT'S LIQUIDITY CONTRACT WITH CM-CIC SECURITIES
|
English | 398.1 KB | ||
| 2013-11-22 08:30 |
GFT505 : La sélection des patients de l’étude de Phase IIb s’achève avec succès
|
French | 780.5 KB | ||
| 2013-11-22 08:30 |
GFT505: Patient selection for the phase IIb study is successfully completed
|
English | 523.3 KB | ||
| 2013-10-25 18:45 |
GENFIT: Half-Year results for 2013
|
English | 453.1 KB | ||
| 2013-10-25 18:45 |
GENFIT : Résultats du 1er semestre 2013
|
French | 563.6 KB |
Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GENFIT
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GENFIT via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-07-07 | N/A | Other | Buy | 5,300 | 19,488.10 EUR |
| 2023-07-06 | N/A | Other | Buy | 1,100 | 4,048.00 EUR |
| 2023-07-05 | N/A | Other | Buy | 10,000 | 37,061.00 EUR |
| 2023-07-03 | N/A | Other | Buy | 5,300 | 18,769.95 EUR |
Peer Companies
